医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Five Year Peak Sales Forecast of Newly Reimbursed Drugs in Japan Surges to $34bn

2015年03月10日 PM10:00
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & TOKYO

Despite depreciation of the Japanese Yen, the overall output of the Japanese drug industry measured by expected peak sales potential of newly National Health Insurance (NHI) reimbursed drugs surged to $34 billion between 2010-2014, up from $16.9 billion during 2005-2009 according to Evaluate’s new report “Japan Sales, Volume, Pricing 2015.”

“Japan is the second largest prescription drug market in the world, with soft patent erosion and a favourable payer environment,” said Anthony Raeside, Evaluate’s head of research. “The peak sales potential of newly reimbursed drugs has more than doubled since 2009 illustrating the importance of this market. Though strong growth opportunities exist, commercial success requires a deep understanding of the pricing environment as drug prices are essentially fixed at launch.”

The report was derived from Evaluate’s new EvaluatePharma Japan Sales, Volume, Pricing Intelligence, which is now available alongside the US analysis and fully integrated into the service. For pharmaceutical companies looking to launch products or conduct business development in Japan, this new analysis provides an integrated, single source for current and historic pricing, approval details and cost per patient analysis. For Japan-based companies, it allows them to easily analyse the local market and make global market price comparisons to optimise new product launches and growth opportunities. Dual language fields and links to Japan source documents are included.

Key highlights of the report include:

  • Peak sales forecast of newly reimbursed drugs surged to $34 billion between 2010-14 compared to $16.9 billion during 2005-09
  • Quantity of reimbursed drugs increased 8 percent to 64 in 2014 vs. 2013; peak sales forecasts increased 19 percent in 2014 to $6.3 billion
  • The median reimbursed price for Japanese drugs between 2005-14 was 40 percent lower than the US; 20 percent lower than Germany
  • New endocrine drugs have the highest peak sales potential with central nervous system drugs coming in second
  • Median annual cost of new drugs jumped to $837 (¥95k) in 2010-14 from $697 (¥82k) in 2005-09

The full version of the report can be downloaded at www.evaluategroup.com/JapanSalesVolumePricing2015. For more information on the new Japan and USA Sales, Volume, Pricing enhancement included within the EvaluatePharma service, visit www.evaluate.com.

About Evaluate Ltd.

Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. Our services include EvaluatePharmaEvaluateClinical Trials and EvaluateMedTech. Our award-winning editorial team, EP Vantage, leverages our strategic analysis to cut through the noise, giving you daily opinion and insights. The Evaluate services enable the life science community to make sound business decisions about value and opportunity. For more information please visit www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage.

CONTACT

Evaluate and EP Vantage (for general questions)
Christine Lindgren,
+1 617-866-3906
christine.lindgren@evaluategroup.com
or
Chempetitive
Group (for U.S. media)
Rachel Wallace, +1 781-775-3640
rwallace@chempetitive.com
or
Instinctif
Partners (for non-U.S. media)
Gemma Howe, +44 (0) 20 7457 2020
evaluate@instinctif.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持